SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

PRODUCT NAME: **Lidocaine Ointment USP, 5%** **PRODUCT No.:** 51672-3020

Distributor: Taro Pharmaceuticals U.S.A., Inc.
3 Skyline Drive, Hawthorne, New York 10532
Telephone: 1-888-TARO-USA

Recommended Use: Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx.

It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites.

Restrictions on Use: Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of Lidocaine Ointment USP, 5%.

SUBSTANCE CLASS: Anesthetic (local)

FORMULA: $C_{14}H_{22}N_2O$

M.W.: 234.34

SECTION 2: HAZARD(S) IDENTIFICATION

EMERGENCY OVERVIEW: Effects of overexposure: Systemic effects may include nervousness, confusion, drowsiness, blurred vision, vomiting, tremors, convulsions, respiratory depression, slowing of heart, blood pressure drop and unconsciousness.

POTENTIAL HEALTH HAZARDS

Eye: May cause irritation. Eye contact will also cause numbness and loss of sensation. Seek medical/professional assistance immediately.

Skin: No special protection needed. If skin contact occurs, wash thoroughly with water.

Ingestion: May result in toxic effects on the Central Nervous System and on the cardiovascular system. Allergic reactions may also occur. If ingested contact a Poison Control Center immediately.

Inhalation: Not applicable.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient:	Lidocaine USP, 5%	CAS#: 137-58-6
Inactive Ingredients:	Polyethylene glycol 400, polyethylene glycol 3350, and propylene glycol.	

SECTION 4: FIRST-AID MEASURES

Inhalation	If vapors of this product are inhaled, causing irritation, remove victim to fresh air. If necessary, use artificial respiration to support vital functions. Seek medical attention if adverse effect continues after removal to fresh air.
Ingestion	If this product is swallowed, call physician or poison control center for most current information. If professional advice is not available, do not induce vomiting. Never induce vomiting or give diluents (milk or water) to someone who is unconscious, having convulsions, or unable to swallow. If victim is convulsing, maintain an open airway and obtain immediate medical attention.
Skin Contact	If adverse skin effects occur, discontinue use. Seek medical attention.
Eye Contact	If this product contaminates the eyes, rinse eyes under gently running water. Use sufficient force to open eyelids and then "roll" eyes while flushing. Minimum flushing is for 15 minutes. The contaminated individual must seek medical attention if any adverse effect continues after rinsing.

SECTION 5: FIRE-FIGHTING MEASURES

Flash Point:	Not applicable
Extinguishing Media:	Extinguish fires with CO_2
Special Fire Fighting Procedures:	None
Unusual Fire And Explosion Hazards:	None
Hazardous Combustion Products:	Non-hazardous

SECTION 6: ACCIDENTAL RELEASE MEASURES

Clean up spills with normal procedures used for non-hazardous semi-solids. Dispose as a non-hazardous waste and in accordance with Federal, State and local regulations.

SECTION 7: HANDLING AND STORAGE

HANDLING:	No special handling required. Pharmacist should dispense in tight containers as specified in USP. If dispensed to a consumer, provide child resistant package.
STORAGE:	Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from freezing.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS:	N/A
PERSONAL PROTECTION:	
Respiratory:	Not needed
Eye:	Not needed
Clothing:	Not needed
Gloves:	Not needed
WORK PRACTICES:	Use normal work practices.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

BOILING POINT:	Not applicable
PHYSICAL STATE (liquid/solid/gas):	Solid
SPECIFIC GRAVITY (H2O=1):	Not applicable
EVAPORATION RATE (Butyl Acetate=1):	Slower than ether
SOLUBILITY:	Not applicable
APPEARANCE:	Off white, translucent unctuous mass

SECTION 10: STABILITY AND REACTIVITY

Chemical Stability:	Stable
Conditions to Avoid:	None
Incompatibility with other Materials:	None
Hazardous Decomposition Products:	None
Hazardous Polymerization:	Will not occur
Material To Avoid:	None

SECTION 11: TOXICOLOGICAL INFORMATION

Ingestion may result in toxic effects on the Central Nervous System and on the cardiovascular system. See package insert for complete Warnings.

SECTION 12: ECOLOGICAL INFORMATION

No data available.

SECTION 13: DISPOSAL CONSIDERATIONS

Clean with water and dispose of in accordance with Federal, State and local regulations.

SECTION 14: TRANSPORT INFORMATION

U.S. Department of Transportation Shipping Regulations:
This product is not classified as hazardous under regulations of U.S. DOT 49 CFR 172.101

Transport Canada Transportation of Dangerous Goods Regulations:
This product is not classified as Dangerous Goods, per regulations of Transport Canada.

SECTION 15: REGULATORY INFORMATION

Taro Pharmaceuticals U.S.A., Inc.
Attn: Regulatory Affairs Department
3 Skyline Drive
Hawthorne, NY 10532
(914) 345-9001
(914) 593-0078 fax

SECTION 16: OTHER INFORMATION

Contact: Taro Pharmaceuticals U.S.A., Inc., Regulatory Affairs Department
3 Skyline Drive, Hawthorne, NY 10532

Preparation and/or Revision Date: May 2017

D I S C L A I M E R

The above information has been obtained from a number of sources and its accuracy cannot be guaranteed. It is the user's responsibility to evaluate the information and use it in a prudent manner for its particular purpose. Taro Pharmaceuticals assumes no responsibility for the use of this information.